Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IDEAYA Biosciences (IDYA) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for IDEAYA Biosciences (IDYA) over the last 6 years, with Q2 2025 value amounting to $88.5 million.

  • IDEAYA Biosciences' Shares Outstanding (Weighted Average) rose 1348.01% to $88.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $88.5 million, marking a year-over-year increase of 1348.01%. This contributed to the annual value of $41.4 million for FY2022, which is 1756.55% up from last year.
  • According to the latest figures from Q2 2025, IDEAYA Biosciences' Shares Outstanding (Weighted Average) is $88.5 million, which was up 1348.01% from $88.4 million recorded in Q1 2025.
  • IDEAYA Biosciences' Shares Outstanding (Weighted Average)'s 5-year high stood at $88.5 million during Q2 2025, with a 5-year trough of $35.3 million in Q4 2021.
  • In the last 5 years, IDEAYA Biosciences' Shares Outstanding (Weighted Average) had a median value of $60.0 million in 2023 and averaged $63.4 million.
  • Per our database at Business Quant, IDEAYA Biosciences' Shares Outstanding (Weighted Average) soared by 5527.88% in 2024 and then surged by 1348.01% in 2025.
  • IDEAYA Biosciences' Shares Outstanding (Weighted Average) (Quarter) stood at $35.3 million in 2021, then rose by 17.57% to $41.4 million in 2022, then soared by 44.77% to $60.0 million in 2023, then surged by 43.65% to $86.2 million in 2024, then grew by 2.65% to $88.5 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $88.5 million in Q2 2025, compared to $88.4 million in Q1 2025 and $86.2 million in Q3 2024.